Proprius Pharmaceuticals
A San Diego innovator specializing in rheumatology and autoimmune care, offering promising early-stage treatments for pain and rheumatoid arthritis since 2005.
A San Diego innovator specializing in rheumatology and autoimmune care, offering promising early-stage treatments for pain and rheumatoid arthritis since 2005.
Proprius Pharmaceuticals, a San Diego-based biotechnology and pharmaceutical company, has been a pioneering force in the field of rheumatology and autoimmune care since its establishment in 2005. Specializing in the development of drugs for these ailments, Proprius Pharmaceuticals is currently advancing two early-stage therapeutic candidates, one targeting pain management and the other focusing on rheumatoid arthritis treatment. With a $11.00M Series A investment received on 08 January 2007, the company's noteworthy investors include Atlas Venture, Forward Ventures, Fog City Capital, Windamere Venture Partners, and CDIB BioScience Ventures. Proprius Pharmaceuticals continues to be devoted to creating innovative solutions in the medical field, making significant strides in tackling these complex and impactful conditions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $11.00M | 5 |
|
08 Jan 2007 |
No recent news or press coverage available for Proprius Pharmaceuticals.
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.